#Canada #financial results #Calgary #Nanalysis #NMR Technology

Nanalysis Scientific Corp. Financial Results for Q4 and Full Year 2025

Nanalysis Scientific Corp., a leader in portable NMR spectrometers and MRI technology, has shared its financial performance for the fourth quarter and the entire year of 2025. The report highlights significant strategic initiatives aimed at fostering operational improvements and enhancing growth potential for the future.

In the fourth quarter, Nanalysis recorded a revenue of CAD 10.7 million, which represents a 13% decrease from the same period in 2024. For the entire year, the company's revenue tallied at CAD 40.1 million, marking a 12% decline year-over-year. Despite these downturns, the company achieved an Adjusted EBITDA of CAD 1.2 million in the fourth quarter, signaling a return to positive profitability after a challenging period of fluctuating revenue streams.

CEO Sean Krakiwsky commented on these results, stating, "We made meaningful progress in 2025 despite a challenging operating environment. Our actions to strengthen leadership, enhance service operations, and diversify our sales and supply strategies are beginning to position the company for stronger future performance."

Financial details indicate that product sales dropped by 25% from the previous year quarter while security services revenue showed minimal fluctuation, only decreasing by 1%. Adjusted EBITDA for the quarter was CAD 1,187, down from CAD 1,835 a year prior, attributed to ongoing instability in the scientific instrumentation market. The company is actively diversifying its market strategies to enhance resilience against economic shifts.

Yearly Overview

Analyzing the full year, the total revenue included CAD 13.4 million from product sales, CAD 22.1 million in security services, and CAD 4.5 million in flow-through inventory revenue. The gross margin for product sales improved to 57% and was attributed to enhanced manufacturing efficiencies and cost reductions initiated in prior years.

The company recognized a consolidated net loss of CAD 5.7 million, a notable improvement from a loss of CAD 13.6 million in 2024, primarily due to reduced depreciation expenses after the previous year’s impairments. Nanalysis continues to focus on operational efficiency, aiming to stabilize and improve margins within its service segments moving forward.

Strategic Moves

Throughout 2025, Nanalysis implemented several strategic initiatives, including strengthening supply chain relationships and diversifying its market reach, especially toward European avenues amidst changing global trade dynamics. Increased inventory levels were established for critical components to safeguard against supply disruptions.

Notably, the company secured non-dilutive funding of CAD 1 million via a developmental economic initiative to bolster its diversification measures and supply stability further. A private placement resulted in a reduction of term loans, reinforcing the company’s financial structure.

Looking ahead to 2026, Mr. Krakiwsky expressed optimism, noting, "We are preparing for a stronger 2026, believing that the operational adjustments we have undertaken over the past year will enhance our financial performance. Our commitment to building customer and vendor relationships alongside our innovative technology positions us well for ongoing growth and value delivery to shareholders."

As Nanalysis navigates the complexities of the market landscape, it remains focused on enhancing profitability and operational performance while delivering quality service to its customers. All interested stakeholders are encouraged to join the upcoming conference call on April 9th to gain further insights into the company’s fiscal performance and strategic directions.

In conclusion, Nanalysis Scientific Corp. is poised to leverage its strength in the scientific domain, aiming for consistent execution and growth amidst the challenges of the current market, reaffirming its commitment to innovation in NMR technology.